Press Releases
Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy
"I am encouraged with the totality of the data presented today, which show that median event-free ages for SMA infants in both the 6 mg and 12 mg cohorts compare favorably to that observed in a recent natural history study. These data combined with the safety and tolerability profile observed to date support my enthusiasm to further evaluate ISIS-SMNRx in a Phase 3 study in infants with Type I SMA," said
Event-free survival data from Phase 2 study in infants with SMA
In the Phase 2 study in infants with SMA, a total of 20 infants were dosed as of
In the 6 mg cohort:
- No patients have had an event (death or permanent ventilation) since April 2014. As of
September 2, 2014 , there have been two events (one accidental death and one permanent ventilation) in the 6 mg cohort. - Isis previously reported a median event-free age of 14 months for the infants in the PPEP on
April 7, 2014 . The median event-free age onSeptember 2, 2014 for the infants in this group is now 16.3 months.
In the 12 mg cohort:
- Dosing in the 12 mg cohort began five months after the initiation of dosing for the 6 mg cohort. As a result, the patients in the 12 mg cohort have participated in the study for a shorter time than those in the 6 mg cohort. As of
April 7 , the PPEP in the 12 mg dose cohort contained 7 infants. As ofSeptember 2 , the PPEP for the 12 mg dose cohort contained 12 infants, which included an additional five infants who had more recently entered the study. - Isis previously reported a median event-free age of 9.6 months for the infants who constituted the 12 mg PPEP as of
April 7, 2014 . The median event-free age atSeptember 2, 2014 for these infants is now 13.8 months. - The median event-free age of the 12 infants in the PPEP as of
September 2, 2014 for the 12 mg cohort is 11.6 months. Of these 12 infants, nine are alive without the need for permanent ventilation. - As of
September 2, 2014 , there have been four events (one permanent ventilation and three deaths, all related to respiratory infections) in the 16 infants from the 12 mg cohort.
Increases in muscle function scores in this study in infants with SMA
Measures of muscle function are also being assessed in this study. Increases in muscle function scores were observed in infants in both dosing cohorts using the
- Increases in CHOP INTEND scores occurred in a majority of infants in the study. Infants in the PPEP from the 6 mg and 12 mg cohorts combined showed mean increases from baseline in CHOP INTEND of 9.3 points with 14 of the 16 infants showing an increase in CHOP INTEND scores.
- Infants from the 12 mg dose cohort PPEP showed mean increases from baseline in CHOP INTEND of 11.7 points with 11 of the 12 infants showing an increase in CHOP INTEND scores.
Developmental milestones are also being examined in this study using the Motor Milestones portion of the Hammersmith Infant Neurological Examination, with 14 out of the 16 infants in the combined PPEP exhibiting improvements in motor milestones.
The safety and tolerability profile of ISIS-SMNRx to date supports continued development. As of
Clinical data on ISIS-SMNRx Mechanism of Action
Today, Isis reported the results from an analysis of spinal cord tissue samples from autopsies showing that ISIS-SMNRx is distributed throughout the central nervous system. The results of these analyses also showed greater levels of full length SMN2 mRNA and full length SMN protein in tissues in ISIS-SMNRx-treated SMA infants compared to the levels of SMN2 mRNA and full length SMN protein in the tissues analyzed from untreated SMA infants. These analyses were conducted on tissue samples collected in three infants who had received three or more doses of ISIS-SMNRx and were compared to tissue samples from four untreated SMA infants and three infants without SMA at a similar age range.
- Analysis of spinal cord tissue showed that ISIS-SMNRx concentration in spinal cord tissues was greater than the concentration that resulted in biological activity in animal studies. ISIS-SMNRx was found in multiple segments of the spinal cord and brain and in motor neurons.
- Greater level of full-length (containing exon 7) SMN2 mRNA was observed in the spinal cord and brain tissue of ISIS-SMNRx-treated SMA infants compared to the level of full-length SMN2 mRNA in the untreated SMA infants.
- In patients treated with ISIS-SMNRx, greater amounts of SMN protein were observed in the spinal cord compared to the amount of SMN protein observed in the untreated SMA infants.
- SMN protein was observed in neurons of tissues analyzed in ISIS-SMNRx-treated SMA infants in which ISIS-SMNRx was present.
"The results on ISIS-SMNRx presented today form an encouraging profile of a potential new therapy for patients with SMA," continued Dr. Finkel. "The consistency of observations in event-free survival, CHOP INTEND and development milestones, combined with the clinical data supporting the mechanism of action by which ISIS-SMNRx was designed to act, creates strong support to continue evaluation of ISIS-SMNRx."
"We are encouraged that we have been able to evaluate both the distribution of ISIS-SMNRx in spinal cord tissues and motor neurons, and the levels of full length SMN protein in the spinal cord of ISIS-SMNRx-treated infants. We are very fortunate to have access to these tissue samples, and thankful to the families who have allowed us to use them to advance the study of SMA and ISIS-SMNRx. Access to these tissues has enabled us to confirm what we observed in our earlier preclinical work; that ISIS-SMNRx is broadly distributed throughout the central nervous system of ISIS-SMNRx-treated infants. We are also pleased to observe that the levels of ISIS-SMNRx in tissues analyzed from ISIS-SMNRx-treated infants are greater than the concentrations at which we observed biological activity in our animal studies. We are also encouraged with the greater levels of full-length SMN2 mRNA and commensurate increases in SMN protein we observed in tissues analyzed from ISIS-SMNRx-treated SMA infants as compared to the levels of full-length SMN2 mRNA and SMN protein we observed in tissues analyzed from untreated SMA infants," said
Results from Phase 2 study in children with SMA
In the ongoing, open-label study in children with SMA, increases in muscle function scores, as measured by the Hammersmith Functional Motor Scale-Expanded (HFMSE), were observed in children treated with multiple doses of ISIS-SMNRx. As previously reported in
Increases in two additional functional tests were also observed eight to 13 months after last dose in the six-minute walk test (6MWT) and the upper limb mobility (ULM) test. In the 6MWT, performed with 10 ambulatory children, a mean increase of 24.4 meters was observed 12 to 16 months after the patients' baseline visits, compared to the previously reported increase of 22.7 meters at nine months. In the ULM test, a mean increase of 3.1 points was observed 11 to 16 months after the patients' baseline visits, compared to the previously reported increase of 2.3 points at nine months.
The safety and tolerability profile of ISIS-SMNRx continues to support continued development. As of
"SMA is a heartbreaking disease. Children with SMA are bright and engaging, but due to progressive muscle weakness, grow weaker over time and suffer a decline in their physical abilities. Because of the inevitable gradual decline that patients with SMA exhibit, I am encouraged with the consistency of the muscle function scores in these children. Not only do these children experience increases in muscle function scores, even after a single dose of ISIS-SMNRx, but it now appears that these increases can be sustained for a significant time after dosing," said
"The consistency of the increases in muscle function scores across different SMA patient populations, including both children and infants with SMA, and the dose- and time-dependency of these increases is encouraging. The observation of increases in SMN protein in the spinal cord in tissues analyzed from ISIS-SMNRx-treated infants, suggest that ISIS-SMNRx is acting by the mechanism of action through which it was designed to act," concluded Dr. Bennett.
Investor Event
At
ABOUT ISIS-SMNRx
ISIS-SMNRx is designed to alter the splicing of a closely related gene (SMN2) to increase production of fully functional SMN protein.
ISIS-SMNRx is being evaluated in a pivotal Phase 3 study, ENDEAR, in infants with SMA. The ENDEAR study is a randomized, double-blind, sham-procedure controlled thirteen month study in approximately 110 infants diagnosed with SMA. The study will evaluate the efficacy and safety of a 12 mg dose of ISIS-SMNRx with a primary endpoint of survival or permanent ventilation. Additional efficacy endpoints are also included in the study. For further study information, please visit www.clinicaltrials.gov and search for ISIS-SMNRx or the identifier number NCT02193074 or visit the ISIS-SMNRx study site at www.smastudy.com.
Isis acknowledges support from the following organizations for ISIS-SMNRx:
ABOUT SMA
SMA is a severe genetic disease that affects approximately 30,000-35,000 patients in
ABOUT ISIS and
ABOUT
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in
This press release includes forward-looking statements regarding Isis' alliance with
In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to
Isis Pharmaceuticals® is a registered trademark of
Logo - http://photos.prnewswire.com/prnh/20130807/LA60006LOGO
SOURCE
D. Wade Walke, Ph.D., Vice President, Corporate Communications and Investor Relations, 760-603-2741; Amy Blackley, Ph.D., Associate Director, Corporate Communications, 760-603-2772